Tenaya Therapeutics (TNYA) Accumulated Depreciation (2020 - 2026)

Tenaya Therapeutics has reported Accumulated Depreciation for 7 years, with the latest figure at $41.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation rose 19.3% year-over-year to $41.7 million; the trailing twelve-month figure through Mar 2026 stood at $41.7 million (up 19.3% YoY), and the FY2025 full-year result was $39.9 million, up 23.67% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $41.7 million, up from $39.9 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $41.7 million in Q1 2026, with the low at $10.4 million in Q1 2022.
• Average Accumulated Depreciation over 5 years is $26.2 million, with a median of $26.5 million recorded in 2024.
• Year-over-year, Accumulated Depreciation surged 74.09% in 2023 and grew 19.3% in 2026.
• Tracing TNYA's Accumulated Depreciation over 5 years: stood at $15.7 million in 2022, then soared by 55.27% to $24.3 million in 2023, then soared by 32.66% to $32.3 million in 2024, then gained by 23.67% to $39.9 million in 2025, then grew by 4.41% to $41.7 million in 2026.
• The last three Accumulated Depreciation figures came in at $41.7 million (Q1 2026), $39.9 million (Q4 2025), and $38.9 million (Q3 2025), per Business Quant data.

Peer Comparison